Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics

Figures & data

Figure 1 Regional distribution of respondents according to mental health settings where the respondents performed professional activities.

Table 1 Characteristics of the overall population of survey respondents

Characteristics	Percentage of respondents
Sex
Male	38
Female	25
Not specified	37
Place of work
Community mental health centers/community-based institutions	60
Inpatient hospitals	27
Private practice	8
Rehabilitation setting	5
Years of professional experience
≤10 years	14
11–20 years	15
21–30 years	16
>30 years	2
No response	53

Figure 2 Suggested parameters to be considered when evaluating the success of an antipsychotic therapy in patients with schizophrenia.

Notes: Responses to the question “Which parameters do you consider when evaluating the success of antipsychotic therapy in patients suffering from schizophrenia?” Percentage of the total number of times the specific domain has been reported in answering this open-ended unsolicited question by the 709 respondents.

Figure 3 Domains of importance of preset responses when assessing treatment success rated from 1 (not important) to 7 (of utmost importance) by psychiatrists treating patients suffering from schizophrenia.

Notes: Responses to the question “How important do you think are the following items, except for the therapeutic efficacy, when assessing the success of an antipsychotic therapy in a patient with schizophrenia?” Percentage of responses mentioning the specific domain from a cohort of 709 respondents.

Figure 4 Psychiatrists’ understanding of quality of life (QoL) in patients with schizophrenia.

Notes: Responses to the question “What do you mean by ‘QoL’ in a patient suffering from schizophrenia?” Percentage of responses mentioning the specific domain when clinicians were questioned about the meaning of QoL from a cohort of 709 clinicians.

Figure 5 Importance of preset items when reporting understanding of quality of life (QoL) according to psychiatrists, rated from 1 (not important) to 7 (of utmost importance).

Notes: Responses to the question “Which are the most important items through which you assess the QoL in patients suffering from schizophrenia?” Percentage of responses mentioning the specific domain from a cohort of 709 respondents.

Figure 6 Level of importance of preset clinical outcomes when assessing the success of long-acting injectable treatment, rated from 1 (not important) to 7 (of utmost importance) according to psychiatrists treating patients with schizophrenia.

Notes: Responses to the question “How much importance do you attach to the following clinical outcomes (not including therapeutic efficacy) when assessing the success of long-acting antipsychotic therapy in a patient suffering from schizophrenia?” Percentage of responses mentioning the specific clinical outcomes from a cohort of 709 respondents.

Figure 7 Level of agreement with prescribing long-acting injectable antipsychotic treatment to five preset patient types, rated from 1 (no agreement) to 7 (complete agreement) according to psychiatrists treating patients with schizophrenia.

Notes: Responses to the statement “These patients with schizophrenia are best suited to receiving long-acting antipsychotic therapy”. Percentage of responses mentioning the specific patient type from a cohort of 709 respondents. ^aTreatment failed in these patients due to a lack of patient compliance/not taking medicine.